drugset / Trial / NCT07267481
Switching From Xiidra to TRYPTYR
NaSingle-groupOpen-labelOther
Summary
To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%. Hypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2026-04-15
- Completion
- 2026-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acoltremon | Small molecule | 0.003 % | — |